Chagas Disease drug Discovery // Drug Repurposing

Chagas Disease drug Discovery

Rick L. Tarleton, Ph.D.

Founder and President

Rick has more than 30 years of research experience in various aspects of human and experimental T. cruzi infection and Chagas disease. He was the Founding Director of the Center for Tropical and Emerging Global Diseases (1998-2001) at the University of Georgia and is currently a Distinguished Research Professor at UGA.

Daniel C. Colley, Ph.D.

Board Member

Dan has more than 40 years of experience in tropical disease research in schistosomiasis, Chagas disease, and tracoma. From 1993-2001 he was Director of the Division of Parasitic Diseases at the Center for Disease Control and is currently the Director of the Center for Tropical and Emerging Global Diseases at the University of Georgia where he also directs the Bill and Melinda Gates funded global consortium for operational research in Schistosomiasis. Dan has been the recipient of numerous awards including Brazil's highest scientific honor "Order of Scientific Merit, Class Gra-Cruz" presented by the President of Brazil in 2005.

Ricardo Gurtler, Ph.D.

Board Member

Ric is an Associate Professor at the University of Buenos Aires. His expertise is with the ecoepidemiology of Chagas disease with specific emphasis on infection transmission.

Boris Striepen, D.Sc.

Board Member

Boris is an expert in the cell and molecular biology of apicomplexan parasites, including Toxoplasma gondii and Cryptosporidium. He is an Associate Professor in the Department of Cellular Biology and the Center for Tropical and Emerging Global Diseases at the University of Georgia

Ricardo Preve

Board Member

Mr. Ricardo Preve is Argentinian by birth and is currently head of Ricardo Preve Films LLC ( in Charlottesville, VA where he serves as a Producer and Director. Among his list of successful products is the documentary film "Chagas: A Hidden Affliction".

Michael A. Luther, Ph.D, MBA

Board Member

Dr. Michael Luther is the President of the David H. Murdock Research Institute. Prior to becoming President of the David H. Murdock Research Institute earlier this year, Dr. Luther held the position of Vice President of Basic Research and Site Head at Merck Frosst Centre for Therapeutic Research in Montreal, QC. He headed efforts in drug discovery and development in Inflammation and Metabolic Diseases. Before Merck, Dr. Luther was with GlaxoSmithKline in a number of positions of increasing responsibility including his last role as Vice President in Discovery Research and as the leader of a new business venture that integrated diagnostics and therapeutics called Predictive Medicine.

You might also like

An anecdotal response

by invivoVibrio

I have worked in several labs that have produced, either directly or through a spin-off company, real products that are medically useful. Scientists are the ones who create vaccines, design diagnostic devices and tests, and discover useful drugs.
There's a whole spectrum that falls under the title "science," which ranges from the purely discovery-oriented, focusing on just learning more about a topic for learning's sake; to the purely practical, such as so-called translational research, where scientists iron out the details of a practically useful discovery and optimize it for practical applications, "translating" the basic science into something that can be produced and sold by industry

Academic Press Chagas Disease, Volume 75: Part A (Advances in Parasitology)
Book (Academic Press)

Cancer-Fighting Patch to Treat Mouth Cancer  — Drug Discovery & Development
Ohio State, through the Ohio State Innovation Foundation and the university's Drug Development Institute, and the University of Michigan licensed the intellectual property to the newly formed Sirona Therapeutics.